This Amedeo Smart survey is supported by AngelsInitiative.com.
AmedeoHyperlipoproteinemias |
|
Free Subscription
Circulation |
- May 2026
- WINTERS AH, Kelly MA, Syed MG, Bergquist T, et al
A Genome-First Study of Familial Hypercholesterolemia Comparing African and European Ancestry Individuals.
Circulation. 2026 May 29. doi: 10.1161/CIRCULATIONAHA.126.080694.
>> Share
- VEGA RB, O'Mahony G, Barbour AM, Yu H, et al
Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naive Patients.
Circulation. 2026 May 15. doi: 10.1161/CIRCULATIONAHA.125.075973.
>> Share
March 2026 - MARSTON NA, Bergmark BA, Prohaska TA, Moura FA, et al
Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study.
Circulation. 2026 Mar 30. doi: 10.1161/CIRCULATIONAHA.126.080012.
>> Share
August 2025 - LIU Y, Wang H, Yu M, Cai L, et al
Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm Development and Rupture: Insights From Genetic and Experimental Models.
Circulation. 2025 Aug 5:10.1161/CIRCULATIONAHA.125.074737.
>> Share
July 2025 - WIEGMAN A, Greber-Platzer S, Ali S, Doortje Reijman M, et al
Correction to: Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
Circulation. 2025;152:e22.
>> Share
May 2025 - WIEGMAN A, Peterson AL, Hegele RA, Bruckert E, et al
Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial.
Circulation. 2025 May 20. doi: 10.1161/CIRCULATIONAHA.124.073233.
>> Share
March 2025 - CHUBYKINA U, Vasiluev P, Ivanova O, Ezhov M, et al
The Mysterious Masks of Hypercholesterolemia: A Unique Clinical Case.
Circulation. 2025;151:799-803.
>> Share
November 2024 - LIU J, Bellows BK, Jacobs DR Jr, Woo JG, et al
Low-Density Lipoprotein Cholesterol Level Distributions Across Different Ages: Implications for Screening Children for Severe and Familial Hypercholesterolemia.
Circulation. 2024;150:1741-1744.
>> Share
August 2024 - DAMASE TR, Sukhovershin R, Godin B, Nasir K, et al
Established and Emerging Nucleic Acid Therapies for Familial Hypercholesterolemia.
Circulation. 2024;150:724-735.
>> Share
April 2024 - TAMARGO IA, Baek KI, Xu C, Kang DW, et al
HEG1 Protects Against Atherosclerosis by Regulating Stable Flow-Induced KLF2/4 Expression in Endothelial Cells.
Circulation. 2024;149:1183-1201.
>> Share
February 2024 - STONE NJ, Blum C
If Action is Delayed, Is Survival Denied? Management of Severe Hypercholesterolemia Is Important and Urgent.
Circulation. 2024;149:427-429.
>> Share
January 2024 - SANTOS RD, Cuchel M
LDL-C-Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes.
Circulation. 2024;149:363-366.
>> Share
November 2023 - YALCINKAYA M, Liu W, Thomas LA, Olszewska M, et al
BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in Tet2 Clonal Hematopoiesis.
Circulation. 2023;148:1764-1777.
>> Share
- MILES J, Scotti A, Castagna F, Kuno T, et al
Long-Term Mortality in Patients With Severe Hypercholesterolemia Phenotype From a Racial and Ethnically Diverse US Cohort.
Circulation. 2023 Nov 16. doi: 10.1161/CIRCULATIONAHA.123.064566.
>> Share
October 2023 - WIEGMAN A, Greber-Platzer S, Ali S, Doortje Reijman M, et al
Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
Circulation. 2023 Oct 20. doi: 10.1161/CIRCULATIONAHA.123.065529.
>> Share
- RAAL F, Durst R, Bi R, Talloczy Z, et al
Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.
Circulation. 2023 Oct 18. doi: 10.1161/CIRCULATIONAHA.122.063460.
>> Share
September 2023 - ALDANA-BITAR J, Karlsberg RP, Budoff MJ
Letter by Aldana-Bitar et al Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
Circulation. 2023;148:1057.
>> Share
- PEREZ DE ISLA L, Saltijeral Cerezo A, Mata P
Response by Perez de Isla et al to Letter Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
Circulation. 2023;148:1059-1060.
>> Share
- LONG X, Jiang M
Letter by Long and Jiang Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
Circulation. 2023;148:1058.
>> Share
July 2023 - JOHNS DG, Campeau LC, Banka P, Bautmans A, et al
Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.
Circulation. 2023;148:144-158.
>> Share
May 2023 - ZHANG Y, Dron JS, Bellows BK, Khera AV, et al
Association of Severe Hypercholesterolemia and Familial Hypercholesterolemia Genotype With Risk of Coronary Heart Disease.
Circulation. 2023;147:1556-1559.
>> Share
April 2023 - PEREZ DE ISLA L, Diaz-Diaz JL, Romero MJ, Muniz-Grijalvo O, et al
Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study.
Circulation. 2023 Apr 3. doi: 10.1161/CIRCULATIONAHA.122.062557.
>> Share
February 2023 - PAN C, Herrero-Fernandez B, Borja Almarcha C, Gomez Bris R, et al
Time-Restricted Feeding Enhances Early Atherosclerosis in Hypercholesterolemic Mice.
Circulation. 2023;147:774-777.
>> Share
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016
